Daiken Biomedical Co., Ltd. (TPE:7780)
Taiwan · Delayed Price · Currency is TWD 17.85
+0.05 (0.28%)
At close: Jun 4, 2026
Daiken Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Income | 337.22 | 337.87 | 106.58 | 160.35 | 90.17 |
Depreciation & Amortization | 7.22 | 6.95 | 4.21 | 0.92 | 0.1 |
Provision & Write-off of Bad Debts | 0.01 | 0.02 | 0.88 | 0 | 0 |
Other Operating Activities | 49.91 | 46.42 | -23.94 | 2.25 | 19.36 |
Change in Accounts Receivable | -27.88 | -42.84 | -26.19 | -14.65 | -2.51 |
Change in Inventory | -146.77 | -170.3 | 16.95 | -84.29 | -121.33 |
Change in Accounts Payable | 23.22 | 78.09 | 25.36 | 15.6 | 34.09 |
Change in Unearned Revenue | 3.23 | 2.93 | -22.97 | 8.77 | 5.57 |
Change in Other Net Operating Assets | 53.58 | 13.45 | -29.12 | 16.24 | 16.12 |
Operating Cash Flow | 299.74 | 272.59 | 51.75 | 105.21 | 41.58 |
Operating Cash Flow Growth | 243.79% | 426.73% | -50.81% | 153.01% | - |
Capital Expenditures | -0.39 | -0.39 | -1.25 | - | - |
Sale (Purchase) of Intangibles | -3.78 | -3.4 | -1.97 | - | -0.05 |
Investment in Securities | - | -3,026 | 92.12 | -61.41 | - |
Other Investing Activities | -22.06 | -5.68 | -4.8 | -0.56 | -31.9 |
Investing Cash Flow | -26.23 | -3,035 | 84.09 | -61.96 | -31.95 |
Short-Term Debt Issued | - | 120 | 470 | 183.83 | 33 |
Long-Term Debt Issued | - | - | - | 65 | 127.36 |
Total Debt Issued | 120 | 120 | 470 | 248.83 | 160.36 |
Short-Term Debt Repaid | - | -20 | -628 | -58.83 | - |
Long-Term Debt Repaid | - | -3.25 | -121.24 | -49.42 | -24.36 |
Total Debt Repaid | -23.2 | -23.25 | -749.24 | -108.26 | -24.36 |
Net Debt Issued (Repaid) | 96.8 | 96.75 | -279.24 | 140.58 | 136 |
Issuance of Common Stock | 4,313 | 4,313 | 1,000 | - | - |
Common Dividends Paid | -589.23 | -589.23 | -3.08 | -140.46 | - |
Financing Cash Flow | 3,820 | 3,820 | 717.68 | 0.12 | 136 |
Foreign Exchange Rate Adjustments | 147.89 | 39.17 | -0.86 | - | - |
Net Cash Flow | 4,241 | 1,097 | 852.66 | 43.36 | 145.63 |
Free Cash Flow | 299.35 | 272.21 | 50.5 | 105.21 | 41.58 |
Free Cash Flow Growth | 247.32% | 439.02% | -52.00% | 153.01% | - |
Free Cash Flow Margin | 14.79% | 14.36% | 3.71% | 8.84% | 4.70% |
Free Cash Flow Per Share | 0.37 | 0.41 | 0.12 | 0.47 | 0.27 |
Cash Interest Paid | 1.41 | 0.6 | 6 | 3.36 | 1.18 |
Cash Income Tax Paid | 26.71 | 26.14 | 56.96 | 32.74 | - |
Levered Free Cash Flow | 40.3 | -2,957 | 171.51 | 15.47 | - |
Unlevered Free Cash Flow | 41.18 | -2,957 | 175.26 | 17.57 | - |
Change in Working Capital | -94.63 | -118.67 | -35.99 | -58.33 | -68.06 |